Walleye Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Walleye Capital’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-441,160	Closed	-$11M	–	4475
2025 Q4	$11M	Buy	+441,160	New	+$11.2M	0.03%	591
2025 Q2	–	Sell	-82,199	Closed	-$1.18M	–	4570
2025 Q1	$1.18M	Buy	+82,199	New	+$1.35M	0.01%	1839
2024 Q4	–	Sell	-11,721	Closed	-$187K	–	4932
2024 Q3	$187K	Buy	+11,721	New	+$144K	﹤0.01%	4049

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Walleye Capital's CNTA Position: Q1 2026 in Review

Walleye Capital sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 441,160 shares — an estimated $11M sold.

Walleye Capital first reported a position in CNTA in Q3 2024 and held it in 3 quarters. The position peaked at $11M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Walleye Capital reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 441,160 Centessa Pharmaceuticals shares in Q1 2026, an estimated $11M.
Walleye Capital first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 3 quarters.
Walleye Capital's Centessa Pharmaceuticals position peaked at $11M in Q4 2025.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.